TYRA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
49.0M
+16.7%
42.0M
+15.0%
36.5M
+10.8%
32.9M
+4.7%
31.5M
R&D
39.2M
+17.1%
33.5M
+18.7%
28.2M
+10.7%
25.5M
+4.8%
24.3M
SG&A
9.8M
+15.0%
8.5M
+2.4%
8.3M
+11.4%
7.5M
+4.6%
7.1M
Operating Income
-49003000
-16.7%
-41998000
-15.0%
-36516000
-10.8%
-32944000
-4.7%
-31452000
EBITDA
-48865000
-16.7%
-41860000
-15.1%
-36384000
-10.9%
-32813000
-4.8%
-31312000
Net Income
-45558000
-15.9%
-39305000
-16.2%
-33834000
-13.3%
-29868000
-6.3%
-28098000
EPS (Basic)
$-0.69
-7.8%
$-0.64
-14.3%
$-0.56
-12.0%
$-0.50
-6.4%
$-0.47
EPS (Diluted)
$-0.69
-7.8%
$-0.64
-14.3%
$-0.56
-12.0%
$-0.50
-6.4%
$-0.47
Shares (Diluted)
66.0M
+6.9%
61.7M
+3.2%
59.9M
+0.3%
59.7M
+0.2%
59.6M
Tyra Biosciences (TYRA) โ€” Financials